Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2022-07-18 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
关于子公司获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Dongbei Pharmaceutical Group Co., Ltd. regarding its subsidiary receiving a drug registration certificate from the National Medical Products Administration. It details the drug name, specifications, registration details, and the impact on the company. The document is short (1135 characters) and is an announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category about company operations and approvals, which aligns with Regulatory Filings (RNS).
2022-07-18 Chinese
监事会关于公司2022年限制性股票激励计划首次授予激励对象名单的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from the Supervisory Board regarding the initial grant list of restricted stock incentive plan for 2022. It discusses compliance with company law, securities law, and internal regulations, and confirms the legitimacy of the incentive recipients and the grant details. This is a regulatory compliance and internal verification statement related to stock incentives, not a full financial report, earnings release, or capital update. It is not a report publication announcement or a certification letter but a formal supervisory opinion on stock incentive grants. This fits best under Regulatory Filings (RNS) as it is a regulatory compliance document that does not fit other specific categories like Capital/Financing Update or Share Issue/Capital Change, since it is about verification and approval of incentive stock grants rather than a direct capital change announcement.
2022-07-14 Chinese
北京德恒律师事务所关于东北制药集团股份有限公司2022年限制性股票激励计划调整首次授予部分授予价格、授予激励对象名单及授予数量和首次授予相关事项的法律意见书
Share Issue/Capital Change Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the adjustment and initial grant of a 2022 restricted stock incentive plan by a company. It discusses legal compliance, approvals by the board and shareholders, and details about the stock incentive plan's grant price, recipients, and quantities. There are no financial statements, earnings data, or management discussion of financial results. The document is a legal opinion related to a capital incentive plan, which is closely related to share issuance and capital changes. It is not a full financial report, audit report, or earnings release. Given the focus on stock incentive plan adjustments and grant details, the most appropriate classification is Share Issue/Capital Change (SHA). The document length is about 5795 characters, which is sufficient for a substantive legal opinion rather than a brief announcement or certification, so it is not RPA or RNS.
2022-07-14 Chinese
关于调整公司2022年限制性股票激励计划首次授予部分激励对象名单、授予价格及授予数量的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from a company regarding adjustments to its 2022 restricted stock incentive plan, including changes to the list of incentive recipients, grant prices, and quantities. It details board and supervisory meetings, legal opinions, and compliance with regulatory requirements. The document is relatively short (3268 characters) and focuses on the announcement of changes to a stock incentive plan rather than presenting full financial statements or detailed financial performance data. It does not contain quarterly or annual financial results, audit opinions, or management discussion and analysis. The content fits best with announcements related to share-based compensation plans and capital changes. Therefore, the document is best classified as a Share Issue/Capital Change (SHA) announcement, as it relates to adjustments in stock grants and share allocations under an incentive plan.
2022-07-14 Chinese
关于向激励对象首次授予限制性股票的公告
Share Issue/Capital Change Classification · 100% confidence The document is a detailed announcement regarding the initial grant of restricted shares under a stock incentive plan by Dongbei Pharmaceutical Group Co., Ltd. It includes specifics such as the grant date, number of shares, price, eligibility criteria, performance conditions, and legal opinions. The content focuses on the company's stock incentive plan and the granting of restricted stock to management and key personnel. This type of document is a formal announcement about a capital change related to share issuance to employees or insiders, rather than a financial report or management discussion. It does not contain financial statements or earnings data, nor is it a regulatory certification or a proxy statement. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement or a simple notice, but a full disclosure of a share issuance event.
2022-07-14 Chinese
第九届监事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a supervisory board meeting of Dongbei Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, and voting results on specific agenda items related to adjustments in the company's 2022 restricted stock incentive plan, including grant price, list of incentive recipients, and grant quantities. The document does not contain financial statements or detailed financial analysis but rather reports on governance decisions and approvals by the supervisory board. It is not an annual report, audit report, earnings release, or any financial report. It is also not a proxy solicitation or voting results announcement. The content fits best under Board/Management Information (MANG) as it relates to internal governance decisions and approvals by the supervisory board regarding stock incentive plans.
2022-07-14 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.